Global Health

What we do

Millions of people die every year because they do not have access to effective medication for preventable medical conditions. MIPS researchers are working to improve this situation and deliver equitable healthcare to those in greatest need. Our major activities focus on infectious diseases and maternal, child and reproductive health, along with capacity-building programs for pharmacy globally. Our research ranges from the discovery and development of new drugs, vaccines and diagnostics, to improving medicines and treatment regimens to suit specific populations. Existing collaborations operate in the Pacific, South and Southeast Asia and sub-Saharan Africa and we look to expand our reach further, aligning our activities with local, national and international frameworks to make a positive impact on global health.

Our focus

Infectious Disease View

Maternal, Child and Reproductive health View

Capacity Building for Pharmacy View

Program coordinators

Our highlights

person wearing a white lab coat performing chemistry experiments in a fume hood

Drug discovery platform receives funding, providing a new approach for infectious and chronic disease treatments

The MIPS group will focus on responding to the risk of viral and bacterial replication through the development of a platform capability in polynucleotide fragment based drug design that is better able to discover small-molecules for targeting RNA

CMUS and Monash University Malaysia host joint workshop on pharmacoepidemiology

The workshop sought to build research capacity in the analysis, interpretation and reporting of medication data for the purpose of improving clinical practice.

The Inhaled Oxytocin Project team

Clinical trial of inhaled oxytocin to reduce maternal mortality underway in Melbourne

A Phase 1 clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne.

South African delegation visits MIPS, scientists showcase mRNA innovations

MIPS has welcomed representatives from South Africa’s Afrigen Biologics and the South African Medical Research Council, along with mRNA Victoria, to meet with MIPS mRNA researchers who are working to identify and select promising therapeutic

Monash establishes new initiative to tackle inadequate access to safe and effective medicines in low-and middle-income countries

The initiative, co-founded by Pete Lambert and Professor Michelle McIntosh from MIPS, has been made possible due to a generous grant from The Ripple Foundation.

Dr Harry Al-Wassiti

MRFF back Monash mRNA researchers

The Commonwealth Government’s Medical Research Future Fund has invested $5 million into a new Monash laboratory dedicated to developing mRNA vaccines and therapeutics for future clinical trials.

vaccination concept image with coronavirus

Broad spectrum antiviral, pegylated interferon lambda, found to be highly effective for early treatment of COVID-19 across dominant variants

A new Phase 3 study has found that patients infected with COVID-19 were significantly less likely to be hospitalised or visit emergency departments when treated early with the antiviral drug pegylated interferon lambda.

New investment takes hepatitis B research one step closer to finding a cure

Melbourne scientists have been awarded $1.7 million over the next five years to advance world-first research into a cure for hepatitis B virus infection thanks to a grant from the mRNA Victoria Activation Program.

Antibiotic Discovered at Monash Shows Promising Results in Clinical Trials

QPX9003, a novel antibiotic developed by Monash University researchers targeting antibiotic-resistant ‘superbugs’ has achieved an important milestone in its clinical development, with the initial Phase 1 studies of the drug delivering

Other Therapeutic Program Areas